Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy Volunteers

Inclusion Criteria: * Healthy adults aged ≥ 19 and ≤ 55 years at screening * Subjects with body weight of ≥ 55.0 kg and ≤ 90.0 kg, and a body mass index (BMI) of ≥ 18.0 and ≤ 29.9 * Subjects who have no congenital or chronic disease and have no pathological symptoms or findings as a result of an internal examination Exclusion Criteria: * Subjects with current or prior history of a clinically significant hepatic, renal, nervous, respiratory, gastrointestinal, endocrine, hematologic and oncologic, urogenital, cardiovascular, musculoskeletal or psychiatric disorder * Subjects with symptoms of acute disease within 28 days prior to the scheduled first administration date of IP * Subjects with a history of gastrointestinal diseases (e.g., Crohn's disease, ulcers, etc.) or gastrointestinal resection (except simple appendectomy or hernia surgery) that may affect the absorption of drugs.